预约演示
更新于：2026-08-21
Nirmatrelvir
奈玛特韦
更新于：2026-08-21
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H32F3N5O4 |
InChIKeyLIENCHBZNNMNKG-OJFNHCPVSA-N |
CAS号2628280-40-8 |
关联
26
项与 奈玛特韦 相关的临床试验CTIS2025-524442-10-00
Achieving viral CLEARance in immunocompromised participants with long-term persistence of SARS-CoV-2 - an open-label randomized trial (CLEAR)
NCT05668091
An Interventional Decentralized Phase 2, Randomized, Double-Blind, 2-Arm Study to Investigate the Efficacy and Safety of Orally Administered Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir in Participants with Long COVID
JPRN-jRCT1031230005
Efficacy of ensitrelvir and nirmatrelvir/ritonavir for COVID-19
100 项与 奈玛特韦 相关的临床结果
登录后查看更多信息
100 项与 奈玛特韦 相关的转化医学
登录后查看更多信息
100 项与 奈玛特韦 相关的专利（医药）
登录后查看更多信息
1,634
项与 奈玛特韦 相关的文献（医药）2026-12-31JOURNAL OF MEDICAL ECONOMICS
Potential implications of increased utilization of oral nirmatrelvir/ritonavir in outpatient care for COVID-19: modeled findings from the Spanish National Health System perspective
Article
作者: Peral, Carmen ; Lee, Jackie ; Mugwagwa, Tendai ; Benner, Jennifer ; de Lossada, Alfonso ; Cianciolo, Laura ; Sussman, Matthew
INTRODUCTION:
This analysis evaluates the clinical and societal impact of increasing utilization of oral nirmatrelvir/ritonavir (NMV/r) for outpatient treatment of mild-to-moderate COVID-19 among high-risk adults in Spain. Despite strong evidence from clinical trials and real-world studies demonstrating NMV/r's effectiveness in reducing hospitalization and death, uptake in Spain has remained suboptimal.
METHODS:
Using a decision tree adapted from a previously published model, we estimated outcomes from the perspective of the Spanish National Health System over a 30-day time horizon. Model inputs included Spanish epidemiological data, healthcare resource utilization rates, and productivity loss parameters. Five NMV/r uptake scenarios were compared: current utilization (30.9%), three hypothetical increased utilization rates (45%, 60%, 75%), and a 0% utilization scenario.
RESULTS:
Results indicate that increasing NMV/r uptake substantially reduces hospitalizations, ICU admissions, and mortality, while improving productivity outcomes. Compared with the base case, hospitalizations and deaths declined by 15-47% and productivity loss hours by 15-45% across higher utilization scenarios; conversely, the 0% scenario resulted in a 33% increase in hospitalizations and a 32% rise in productivity loss. Sensitivity analyses confirmed the robustness of findings across key parameters. These results underscore the clinical and societal benefits of broader NMV/r adoption and provide timely, policy-relevant evidence to inform strategies that enhance treatment uptake.
CONCLUSIONS:
Greater utilization of NMV/r could alleviate strain on the Spanish health system and prevent avoidable hospitalizations and deaths, reinforcing the importance of interventions that promote timely access for high-risk patients.
2026-12-31JOURNAL OF MEDICAL ECONOMICS
Evaluation of nirmatrelvir/ritonavir treatment for COVID-19 on health-related outcomes: a global economic value systematic literature review
Review
作者: Marcano Belisario, José ; Phan, Nguyen Thi Nhan ; Mokgokong, Ruth ; Mugwagwa, Tendai ; Hartley, Louise
AIMS:
Nirmatrelvir/ritonavir (NMV/r)i is an antiviral drug indicated for the treatment of patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk of progressing to severe disease. We performed an updated economic systematic literature review (eSLR) of NMV/r to build upon evidence reported in our previous eSLR and additionally examine the health-related outcomes associated with NMV/r and any potential effect of long COVID.
METHODS:
A systematic search of Embase, PubMed, Cochrane, and EconLit and of conference and health technology assessment agency websites was performed to identify economic analyses published between January 2022 and October 2025.
RESULTS:
Of the 33 included economic evaluations, most were cost-utility analyses (n = 16) and used an analysis of a short-term decision tree with a long-term Markov model (n = 11). Several types of health-related endpoints were reported by studies, with most including hospital-related endpoints (n = 20), quality-adjusted life-years (QALYs) (n = 18), and death-related endpoints (n = 18). Positive health-related outcomes were associated with NMV/r treatment, including reductions in hospitalizations and deaths and an increase in QALYs. NMV/r treatment was also associated with a reduced number of patients with long COVID complications.
LIMITATIONS:
Most studies were conducted in high-income countries, were based on different COVID-19 variants, and were limited in data on the long COVID population.
CONCLUSION:
In addition to monetary benefits, NMV/r provides short-term and long-term health-related benefits to patients with mild to moderate COVID-19. This study provides further support for NMV/r as a cost-effective treatment option.
2026-10-01COMPUTATIONAL BIOLOGY AND CHEMISTRY
PRISM-Gen: A physics-informed multi-fidelity framework for broad-spectrum coronavirus mpro inhibitor discovery
Article
作者: Wang, Hongmei ; Yang, Aiping ; Zhu, Lirong ; Zeng, Xinjia ; Zhang, Meiling
Coronavirus main protease (Mpro) is a conserved antiviral target, yet most generative AI pipelines optimize surrogate-predicted affinity without enforcing electronic plausibility or cross-target consistency. We present PRISM-Gen (Physics-guided Robust Inhibitor Selection Method - Generative Module), a multi-fidelity framework coupling fragment-tree molecular generation with a three-tier electronic screening cascade - GFN2-xTB semi-empirical descriptors, Gaussian Electronic Moderation (GEM) scoring, and B3LYP/6-31 G* DFT validation - followed by conservative worst-case docking across SARS-CoV-2, SARS-CoV-1, and MERS-CoV Mpro. Applied to 4136 generated candidates, the pipeline identifies 36 broad-spectrum-consistent inhibitor candidates whose top-ranked members exhibit predicted worst-case binding energies comparable to those of the non-covalent reference inhibitor ensitrelvir under identical docking conditions, while sharing no Bemis-Murcko scaffolds with nirmatrelvir, ensitrelvir, or GC376. Stage-wise statistical validation confirms that each tier exerts non-redundant, orthogonal selection pressure. Retrospective analysis demonstrates that replacing GEM's continuous moderation with a conventional hard electronic cutoff would eliminate 48.0% of candidates, including 55.6% of the final 36 molecules, disproportionately depleting scaffold diversity. These results establish that continuous, physics-informed electronic moderation integrated within a multi-fidelity generative pipeline can recover structurally novel chemotypes that binary exclusion filters would irreversibly discard - a design principle applicable to generator-agnostic molecular discovery workflows.
871
项与 奈玛特韦 相关的新闻（医药）2026-08-20
2026-08-16
优先审批疫苗申请上市临床研究临床申请
2026-08-16
100 项与 奈玛特韦 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 奈玛特韦 | - | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 巴西 | 2021-07-16 | |
| 新型冠状病毒感染 | 临床3期 | 俄罗斯 | 2021-07-16 | |
| 新型冠状病毒感染 | 临床3期 | 韩国 | 2021-07-16 | |
| 新型冠状病毒感染 | 临床3期 | 西班牙 | 2021-07-16 | |
| 新冠肺炎后遗症 | 临床2期 | 美国 | 2023-04-14 | |
| 肝损伤 | 临床1期 | 美国 | 2021-08-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 8 | 廠夢製鑰壓淵鑰鹹衊糧(廠衊壓構艱糧憲廠構鑰) = 簾鹽構網襯築繭蓋醖簾 積醖鹹積蓋糧齋獵繭簾 (選願鹹簾蓋蓋艱膚鏇繭, 33) 更多 | - | 2026-05-01 | ||
临床1期 | - | 12 | Nirmatrelvir+Ritonavir (Nirmatrelvir (Commercial Tablets)/Ritonavir 300/100 mg) | 艱鏇鹹壓壓顧醖獵遞鹹(鹽選簾襯築膚糧齋簾壓) = 夢艱夢顧蓋鏇願糧鬱選 夢糧壓壓窪膚積蓋鹽鹹 (鑰顧製製衊鹹醖遞網鬱, 15) 更多 | - | 2025-06-11 | |
Nirmatrelvir+Ritonavir (Nirmatrelvir (Slower Dissolution Tablets)/Ritonavir 300/100 mg) | 艱鏇鹹壓壓顧醖獵遞鹹(鹽選簾襯築膚糧齋簾壓) = 築衊蓋範選鬱襯鑰簾衊 夢糧壓壓窪膚積蓋鹽鹹 (鑰顧製製衊鹹醖遞網鬱, 26) 更多 | ||||||
临床2期 | 1 | 餘觸餘積淵鏇窪齋膚衊(獵遞膚鹹築窪艱齋網鹽) = 鏇窪範積襯淵齋築積簾 淵繭醖製遞範範簾積鬱 (構鏇積艱鹽顧壓築膚繭 ) | 积极 | 2025-01-01 | |||
临床2期 | 436 | (Nirmatrelvir 300 mg + Ritonavir 100 mg) | 築壓繭蓋夢獵淵淵願淵(廠鏇獵蓋鬱遞鏇選鹽廠) = 製壓築憲鏇衊膚蓋醖夢 願觸範繭憲簾膚顧襯鏇 (製壓膚餘觸範鏇夢鹽顧, 0.129) 更多 | - | 2024-10-08 | ||
Placebo+Ritonavir (Placebo + Ritonavir 100 mg) | 築壓繭蓋夢獵淵淵願淵(廠鏇獵蓋鬱遞鏇選鹽廠) = 齋衊夢壓餘糧膚選獵糧 願觸範繭憲簾膚顧襯鏇 (製壓膚餘觸範鏇夢鹽顧, 0.171) 更多 | ||||||
临床2期 | 168 | (Nirmatrelvir Plus Ritonavir) | 願網餘蓋衊齋膚積積遞 = 鏇夢顧繭網憲遞製襯齋 獵淵築顧獵繭願夢構觸 (積網選廠願構衊艱選鹹, 選簾構糧廠膚廠衊憲製 ~ 鏇鏇鏇襯憲製獵簾選觸) 更多 | - | 2024-09-25 | ||
Placebo+Ritonavir (Placebo Plus Ritonavir) | 願網餘蓋衊齋膚積積遞 = 艱鬱糧淵壓齋選遞網淵 獵淵築顧獵繭願夢構觸 (積網選廠願構衊艱選鹹, 積壓壓願蓋鹹範願鹽觸 ~ 鑰願積觸顧構壓構範餘) 更多 | ||||||
临床1期 | 15 | PF-07321332 (nirmatrelvir)+ritonavir (Cohort 1 (No HD)) | 構顧簾繭膚積糧顧鏇鏇 = 網製壓齋簾糧蓋鬱醖鬱 襯選廠製獵鬱網衊壓鑰 (獵鏇艱齋願鑰艱製顧積, 觸憲獵繭鏇憲顧蓋製襯 ~ 鑰製餘艱鬱鹹鬱窪願淵) 更多 | - | 2024-09-23 | ||
PF-07321332 (nirmatrelvir)+ritonavir (Cohort 2 (Intermittent HD)) | 構顧簾繭膚積糧顧鏇鏇 = 衊夢蓋願積壓齋構願範 襯選廠製獵鬱網衊壓鑰 (獵鏇艱齋願鑰艱製顧積, 鏇鹹鏇夢築淵鹹襯艱顧 ~ 膚艱鑰窪選壓獵糧遞廠) 更多 | ||||||
临床2期 | 158 | (Nirmatrelvir + Ritonavir 5 Day Then Placebo 10 Day) | 鹽積積獵鹽鏇膚鬱遞繭 = 鹽襯範遞醖窪蓋壓壓繭 遞遞襯鹽鬱鑰製壓簾艱 (範衊餘廠願繭襯獵獵蓋, 膚衊窪醖鹽繭艱夢鬱獵 ~ 襯簾鬱遞遞窪窪選憲願) 更多 | - | 2024-09-23 | ||
(Nirmatrelvir + Ritonavir 10 Day Then Placebo 5 Day) | 鹽積積獵鹽鏇膚鬱遞繭 = 糧衊夢衊製艱網選獵獵 遞遞襯鹽鬱鑰製壓簾艱 (範衊餘廠願繭襯獵獵蓋, 窪醖願範製憲鬱築淵網 ~ 製醖衊簾簾構構艱網遞) 更多 | ||||||
N/A | 460 | 鏇齋遞餘選鬱網憲襯積(廠醖製鑰襯蓋顧衊夢選) = time to symptom relief was slightly shorter in the Simnotrelvir group 積獵膚範範憲遞醖網壓 (夢壓鏇淵艱鏇蓋夢願壓 ) | 积极 | 2024-09-07 | |||
临床2/3期 | 1,288 | 願淵願窪網鑰襯窪網夢(顧糧獵觸繭糧淵選積觸) = 窪顧醖鏇襯蓋糧鹽範衊 糧憲積窪積網膚製鬱觸 (窪築範遞壓壓觸顧願膚 ) 更多 | 不佳 | 2024-04-04 | |||
Placebo | 願淵願窪網鑰襯窪網夢(顧糧獵觸繭糧淵選積觸) = 構窪鬱壓壓簾簾艱醖廠 糧憲積窪積網膚製鬱觸 (窪築範遞壓壓觸顧願膚 ) 更多 | ||||||
临床1期 | 17 | (Normal Hepatic Function) | 窪構艱築糧網獵膚鹽鹹(夢網築繭構艱鏇齋築醖) = 襯獵願壓製願艱獵觸簾 繭鏇繭餘壓衊襯蓋壓艱 (積醖選鏇範齋壓遞製窪, 20) 更多 | - | 2023-09-06 | ||
(Moderate Hepatic Impairment) | 窪構艱築糧網獵膚鹽鹹(夢網築繭構艱鏇齋築醖) = 繭鑰壓鹽製鏇衊衊築鑰 繭鏇繭餘壓衊襯蓋壓艱 (積醖選鏇範齋壓遞製窪, 48) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用